IL135154A - Inhbition of lipoprotein oxidation - Google Patents

Inhbition of lipoprotein oxidation

Info

Publication number
IL135154A
IL135154A IL13515498A IL13515498A IL135154A IL 135154 A IL135154 A IL 135154A IL 13515498 A IL13515498 A IL 13515498A IL 13515498 A IL13515498 A IL 13515498A IL 135154 A IL135154 A IL 135154A
Authority
IL
Israel
Prior art keywords
inhbition
lipoprotein oxidation
lipoprotein
oxidation
Prior art date
Application number
IL13515498A
Other languages
English (en)
Other versions
IL135154A0 (en
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL135154A0 publication Critical patent/IL135154A0/xx
Publication of IL135154A publication Critical patent/IL135154A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13515498A 1997-11-25 1998-11-04 Inhbition of lipoprotein oxidation IL135154A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6688897P 1997-11-25 1997-11-25
PCT/US1998/023483 WO1999026583A2 (en) 1997-11-25 1998-11-04 Inhibtion of lipoprotein oxidation

Publications (2)

Publication Number Publication Date
IL135154A0 IL135154A0 (en) 2001-05-20
IL135154A true IL135154A (en) 2005-05-17

Family

ID=22072341

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13515498A IL135154A (en) 1997-11-25 1998-11-04 Inhbition of lipoprotein oxidation

Country Status (23)

Country Link
US (1) US6362236B1 (xx)
EP (1) EP1047421A2 (xx)
JP (1) JP2001523694A (xx)
KR (3) KR100586754B1 (xx)
CN (1) CN1160068C (xx)
AR (1) AR015487A1 (xx)
AU (1) AU759376B2 (xx)
BR (1) BR9815039A (xx)
CA (1) CA2303864A1 (xx)
CO (1) CO4970835A1 (xx)
HK (1) HK1033095A1 (xx)
HU (1) HUP0004396A3 (xx)
IL (1) IL135154A (xx)
IS (1) IS5413A (xx)
NO (1) NO20002639L (xx)
NZ (1) NZ503598A (xx)
PE (1) PE134199A1 (xx)
PL (1) PL341397A1 (xx)
TR (1) TR200001522T2 (xx)
TW (1) TW552137B (xx)
UY (1) UY25268A1 (xx)
WO (1) WO1999026583A2 (xx)
ZA (1) ZA9810743B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US7250304B2 (en) * 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
CA2513660C (en) 2003-01-23 2012-05-08 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US20060194981A1 (en) * 2005-02-26 2006-08-31 Jass Paul A Process for preparation of probucol derivatives
WO2006104399A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP2866801A4 (en) 2012-06-29 2016-02-10 Amarin Pharmaceuticals Ie Ltd METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
KR101665180B1 (ko) 2014-07-01 2016-10-14 순천향대학교 산학협력단 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
CA3144371A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles

Also Published As

Publication number Publication date
PE134199A1 (es) 2000-01-20
WO1999026583A3 (en) 1999-12-09
ZA9810743B (en) 1999-05-31
US6362236B1 (en) 2002-03-26
KR20050086975A (ko) 2005-08-30
CO4970835A1 (es) 2000-11-07
HUP0004396A3 (en) 2003-04-28
NO20002639D0 (no) 2000-05-23
IS5413A (is) 2000-03-24
TW552137B (en) 2003-09-11
UY25268A1 (es) 1999-07-19
EP1047421A2 (en) 2000-11-02
HK1033095A1 (en) 2001-08-17
CN1279605A (zh) 2001-01-10
WO1999026583A2 (en) 1999-06-03
AU759376B2 (en) 2003-04-10
IL135154A0 (en) 2001-05-20
HUP0004396A2 (hu) 2001-06-28
KR100586754B1 (ko) 2006-06-08
JP2001523694A (ja) 2001-11-27
NZ503598A (en) 2002-06-28
KR20050113288A (ko) 2005-12-01
CA2303864A1 (en) 1999-06-03
KR20010032401A (ko) 2001-04-16
AU1518899A (en) 1999-06-15
AR015487A1 (es) 2001-05-02
BR9815039A (pt) 2001-03-20
CN1160068C (zh) 2004-08-04
TR200001522T2 (tr) 2000-12-21
PL341397A1 (en) 2001-04-09
NO20002639L (no) 2000-05-23
KR100539644B1 (ko) 2005-12-29

Similar Documents

Publication Publication Date Title
IL135154A (en) Inhbition of lipoprotein oxidation
HUP0001014A3 (en) Use of gastrointestinal lipase inhibitors
SG71785A1 (en) Deploymerization of polyamides
GB9813227D0 (en) Bearing
GB2354046B (en) Bearing
GB2323652B (en) Means of assembly
HUP0003788A3 (en) Azacycloalkylalkanoyl pseudotetrapeptides intermediates and processes for preparation thereof
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
PL334066A1 (en) Oily composition of dihydropolyprenoles
GB9720087D0 (en) Preparation of cyclopropylethyne and intermediates for preparation of cyclopropylethyne
TW319017U (en) Improved structure of mousetraps
TW321834U (en) Improved structure of balance
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
PL327430A1 (en) Set of shaped components
TW316466U (en) Structure of hangtag
TW314733U (en) Structure of hairclip
TW357554U (en) Improvement of shinguards
TW317745U (en) Improved structure of mini-duster
TW323471U (en) Improved structure of hairclip
TW320911U (en) Improved structure of incense furnace
TW320912U (en) Improved structure of incense furnace
TW336482U (en) Improved structure of an amphora
HU9700245V0 (en) Units of flaw
PL106310U1 (en) Set of books
TW320062U (en) Improved structure of treadmill

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees